BR112022022530A2 - Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk - Google Patents
Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alkInfo
- Publication number
- BR112022022530A2 BR112022022530A2 BR112022022530A BR112022022530A BR112022022530A2 BR 112022022530 A2 BR112022022530 A2 BR 112022022530A2 BR 112022022530 A BR112022022530 A BR 112022022530A BR 112022022530 A BR112022022530 A BR 112022022530A BR 112022022530 A2 BR112022022530 A2 BR 112022022530A2
- Authority
- BR
- Brazil
- Prior art keywords
- ros1
- compound
- cancer
- pharmaceutical composition
- selective inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Abstract
COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE TRATAMENTO DE CÂNCER, MÉTODO DE INIBIÇÃO SELETIVA, MÉTODO DE REDUÇÃO DE UM. NÍVEL DE ROS1 OU ALSão divulgados compostos de éter macrocíclico heteroaromático heterocíclico, sais farmaceuticamente aceitáveis dos compostos e composições farmacêuticas dos mesmos. Também são divulgados métodos de tratamento ou prevenção de câncer usando os compostos de éter macrocíclico heteroaromático heterocíclico, sais farmaceuticamente aceitáveis dos compostos e composições farmacêuticas dos mesmos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2020/088589 | 2020-05-05 | ||
US202063060331P | 2020-08-03 | 2020-08-03 | |
US202063125747P | 2020-12-15 | 2020-12-15 | |
PCT/US2021/030940 WO2021226269A1 (en) | 2020-05-05 | 2021-05-05 | Heteroaromatic macrocyclic ether chemotherapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022022530A2 true BR112022022530A2 (pt) | 2023-02-23 |
Family
ID=78468373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022022530A BR112022022530A2 (pt) | 2020-05-05 | 2021-05-05 | Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk |
Country Status (12)
Country | Link |
---|---|
US (2) | US11667649B2 (pt) |
EP (1) | EP4146205A1 (pt) |
JP (1) | JP2023525040A (pt) |
KR (1) | KR20230005987A (pt) |
AU (1) | AU2021268345A1 (pt) |
BR (1) | BR112022022530A2 (pt) |
CA (1) | CA3179702A1 (pt) |
CL (1) | CL2022003046A1 (pt) |
IL (1) | IL297898A (pt) |
MX (1) | MX2022013051A (pt) |
PE (1) | PE20230309A1 (pt) |
WO (1) | WO2021226269A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL297832A (en) | 2020-05-05 | 2023-01-01 | Nuvalent Inc | Macrocyclic heteroaromatic chemotherapeutic agents |
AU2021268345A1 (en) | 2020-05-05 | 2022-11-10 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
WO2023179600A1 (zh) * | 2022-03-21 | 2023-09-28 | 杭州德睿智药科技有限公司 | 新型取代大杂环类新化合物及其应用 |
TW202400608A (zh) * | 2022-04-07 | 2024-01-01 | 美商努法倫特公司 | 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備 |
WO2023196910A1 (en) | 2022-04-07 | 2023-10-12 | Nuvalent, Inc | Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine |
WO2024054832A1 (en) | 2022-09-09 | 2024-03-14 | Innovo Therapeutics, Inc. | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS |
WO2024074414A1 (en) * | 2022-10-06 | 2024-04-11 | Syngenta Crop Protection Ag | Herbicidal imidazole compounds |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5569655A (en) | 1993-09-14 | 1996-10-29 | Sterling Winthrop Inc. | Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof |
TW401301B (en) | 1994-10-07 | 2000-08-11 | Takeda Chemical Industries Ltd | Antihypertriglyceridemic composition |
AR002459A1 (es) | 1995-01-17 | 1998-03-25 | American Cyanamid Co | Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion. |
US5849735A (en) | 1995-01-17 | 1998-12-15 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
EP1334998B1 (en) | 2000-12-20 | 2006-08-02 | Kyowa Hakko Chemical Co., Ltd. | Metal complex type squarylium compounds and optical recording media made by using the same |
DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
EP2325224A1 (en) | 2002-10-30 | 2011-05-25 | Sumitomo Chemical Company, Limited | Aryl copolymer compounds and polymer light emitting devices made by using the same |
PA8631101A1 (es) | 2004-04-27 | 2006-09-08 | Wyeth Corp | Proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos |
US7514466B2 (en) | 2004-04-27 | 2009-04-07 | Wyeth | Purification of progesterone receptor modulators |
WO2006034090A1 (en) | 2004-09-20 | 2006-03-30 | Janssen Pharmaceutica N.V. | Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators |
US7445211B1 (en) | 2005-03-11 | 2008-11-04 | Walton Daniel J | Wall decoration and game apparatus |
US20070116984A1 (en) | 2005-09-21 | 2007-05-24 | Doosan Corporation | Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same |
US20090022694A1 (en) | 2005-10-18 | 2009-01-22 | Distefano Peter | Sirt1 inhibition |
US20070213526A1 (en) | 2006-03-07 | 2007-09-13 | Wyeth | Purification of progesterone receptor modulators |
GB0609492D0 (en) * | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US7915414B2 (en) | 2006-11-24 | 2011-03-29 | Yun Chi | Blue-emitting organometallic complexes and their application |
FR2913882B1 (fr) | 2007-03-20 | 2009-05-01 | Oreal | Utilisation pour la coloration des fibres keratiniques d'une composition comprenant un compose halochromique et/ou le colorant correspondant a ce compose |
BRPI0813273A2 (pt) | 2007-06-26 | 2014-12-30 | Sanofi Aventis | Síntese catalisada por metal regiosseletivo de benzimidazóis e azabenzimidazóis anelados |
RU2010103101A (ru) | 2007-07-02 | 2011-08-10 | Астразенека Аб (Se) | Химические соединения |
US10189803B2 (en) | 2008-02-22 | 2019-01-29 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
US9446995B2 (en) | 2012-05-21 | 2016-09-20 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
JP2009234928A (ja) | 2008-03-25 | 2009-10-15 | Kyoto Univ | 縮合多環芳香族化合物、およびその製造方法 |
JP5304010B2 (ja) | 2008-04-23 | 2013-10-02 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子、表示装置及び照明装置 |
JP5499519B2 (ja) | 2009-05-27 | 2014-05-21 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子、表示装置及び照明装置 |
MX2012001414A (es) | 2009-08-04 | 2012-03-26 | Tokuyama Corp | Compuesto de cromeno. |
JP4599469B1 (ja) | 2009-08-31 | 2010-12-15 | 富士フイルム株式会社 | 有機電界発光素子用材料及び有機電界発光素子 |
JP2013505252A (ja) | 2009-09-16 | 2013-02-14 | サイリーン ファーマシューティカルズ インコーポレーティッド | 三環式タンパク質キナーゼ調節剤 |
WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
EP2598510A4 (en) | 2010-07-30 | 2014-02-26 | Reddys Lab Ltd Dr | LIGANDS FOR SELECTIVE ASYMMETRIC HYDROFORMYLATION |
WO2012071458A1 (en) | 2010-11-22 | 2012-05-31 | Array Biopharma Inc. | Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases |
DK2655344T3 (da) | 2010-12-22 | 2016-02-01 | Univ Catholique Louvain | Hidtil ukendte phenazin-derivater og deres anvendelse |
FR2969611B1 (fr) | 2010-12-28 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
ES2612492T3 (es) | 2010-12-28 | 2017-05-17 | Sanofi | Nuevos derivados de piridiminas, su preparación y su utilización farmacéutica como inhibidores de fosforilación de AKT (PKB) |
WO2012102409A1 (ja) | 2011-01-27 | 2012-08-02 | 株式会社トクヤマ | クロメン化合物 |
TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子xia抑制劑之新穎巨環化合物 |
CN102977150B (zh) | 2011-09-06 | 2016-07-06 | 郑建鸿 | 含有碳烯配位基的过渡金属错合物结构及其在发光材料的应用 |
CA2863892C (en) | 2012-03-06 | 2016-08-30 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
KR20140032823A (ko) | 2012-09-07 | 2014-03-17 | 롬엔드하스전자재료코리아유한회사 | 유기 전계 발광 소자 |
JP6199752B2 (ja) | 2013-01-24 | 2017-09-20 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子、並びに含窒素複素環化合物 |
WO2014138912A1 (en) | 2013-03-13 | 2014-09-18 | Queen's University At Kingston | Luminescent compounds and methods of using same |
WO2014207606A1 (en) | 2013-06-28 | 2014-12-31 | Pfizer Inc. | Solid forms of a macrocyclic kinase inhibitor |
KR102100929B1 (ko) | 2013-09-04 | 2020-04-14 | 삼성전자주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
KR102167048B1 (ko) | 2013-12-03 | 2020-10-19 | 삼성디스플레이 주식회사 | 화합물 및 이를 포함한 유기 발광 소자 |
EP3091999B1 (en) | 2014-01-09 | 2021-10-20 | Hadasit Medical Research Services and Development Ltd. | Improved cell compositions and methods for cancer therapy |
KR102191992B1 (ko) | 2014-01-22 | 2020-12-17 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
KR102253441B1 (ko) | 2014-03-10 | 2021-05-20 | 삼성디스플레이 주식회사 | 화합물 및 이를 포함한 유기 발광 소자 |
KR101793335B1 (ko) | 2014-09-30 | 2017-11-02 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
US20160140491A1 (en) | 2014-11-17 | 2016-05-19 | Gregory Forgatch | System and method for integrating intermediary and end-user online retail experiences |
US9887372B2 (en) | 2015-06-11 | 2018-02-06 | Samsung Display Co., Ltd. | Amine-based compound and organic light-emitting device including the same |
US10335392B2 (en) | 2015-08-03 | 2019-07-02 | Bristol-Myers Squibb Company | Cyclic compounds useful as modulators of TNF α |
AU2016354661B2 (en) | 2015-11-13 | 2020-12-10 | Domain Therapeutics | Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors |
CN108699081B (zh) | 2016-03-03 | 2019-10-18 | 深圳市塔吉瑞生物医药有限公司 | 一种大环化合物及包含该化合物的组合物 |
CN106243096B (zh) | 2016-07-29 | 2019-11-29 | 上海璃道医药科技有限公司 | 三环类药物的新用途 |
JP6798851B2 (ja) | 2016-10-14 | 2020-12-09 | 株式会社トクヤマ | クロメン化合物、及び該クロメン化合物を含む硬化性組成物 |
CN109528717B (zh) | 2017-09-21 | 2021-08-17 | 中国科学院分子细胞科学卓越创新中心 | 治疗或预防肥胖或其相关疾病的化合物及其应用 |
US20210283261A1 (en) | 2017-12-05 | 2021-09-16 | Icahn School Of Medicine At Mount Sinai | Compositions and Methods for Treating ALK-Mediated Cancer |
WO2019120263A1 (zh) | 2017-12-21 | 2019-06-27 | 广州华睿光电材料有限公司 | 有机混合物及其在有机电子器件中的应用 |
WO2019164301A1 (ko) | 2018-02-21 | 2019-08-29 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR102192368B1 (ko) | 2018-02-28 | 2020-12-17 | 주식회사 엘지화학 | 유기 발광 소자 |
CN110357905B (zh) | 2018-03-26 | 2021-10-01 | 武汉誉祥医药科技有限公司 | 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途 |
CN108912175A (zh) | 2018-06-05 | 2018-11-30 | 长春海谱润斯科技有限公司 | 一种金属铱配合物及其有机发光器件 |
CN112771035A (zh) | 2018-07-26 | 2021-05-07 | 恩特姆生物科学公司 | 用于制备甘露糖衍生物的方法 |
US10593889B1 (en) | 2018-09-26 | 2020-03-17 | Idemitsu Kosan Co., Ltd. | Compound and organic electroluminescence device |
EP3856192A4 (en) | 2018-09-27 | 2023-01-04 | Dana Farber Cancer Institute, Inc. | ALK-TARGETING DEGRADING AGENTS AND THEIR THERAPEUTIC USES |
CN109912433B (zh) | 2019-03-07 | 2022-04-08 | 石家庄诚志永华显示材料有限公司 | 化合物、有机电致发光材料、有机电致发光器件、电子装置 |
KR20200111577A (ko) | 2019-03-19 | 2020-09-29 | 삼성전자주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
WO2020228747A1 (en) | 2019-05-14 | 2020-11-19 | Teligene Ltd | Substituted macrocycles useful as kinase inhibitors |
US20220298130A1 (en) | 2019-08-02 | 2022-09-22 | Duk San Neolux Co., Ltd. | Organic electronic device |
CN112321604A (zh) | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
GB201913756D0 (en) | 2019-09-24 | 2019-11-06 | Chromatwist Ltd | Contrast agent |
CN112812128B (zh) | 2019-11-18 | 2024-04-02 | 正大天晴药业集团股份有限公司 | 作为alk和ros调节剂的大环化合物 |
CN114867732A (zh) | 2019-12-16 | 2022-08-05 | 爱-森新株式会社 | 具有c-n配体的新型过渡金属电子传输络合物及使用其的电化学生物传感器 |
TW202136246A (zh) | 2019-12-19 | 2021-10-01 | 德商麥克專利有限公司 | 電子裝置用化合物 |
CN113121607B (zh) | 2019-12-31 | 2023-07-04 | 马鞍山南大高新技术研究院有限公司 | 一种主配体含喹啉/喹唑啉的红光铱配合物与应用 |
CN111362967B (zh) | 2020-04-28 | 2021-09-07 | 南京雷正医药科技有限公司 | 苯并氧杂二氮杂十四碳烯衍生物及其用途 |
AU2021268345A1 (en) | 2020-05-05 | 2022-11-10 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
IL297832A (en) | 2020-05-05 | 2023-01-01 | Nuvalent Inc | Macrocyclic heteroaromatic chemotherapeutic agents |
CN115362155A (zh) | 2020-07-22 | 2022-11-18 | 中国医药研究开发中心有限公司 | 芳胺类衍生物及其制备方法和医药用途 |
CN111808147B (zh) | 2020-07-28 | 2023-04-18 | 奥来德(上海)光电材料科技有限公司 | 一种有机磷光材料及其制备方法和电致发光器件 |
CN113105440B (zh) | 2021-04-15 | 2022-10-04 | 吉林奥来德光电材料股份有限公司 | 一种有机电致发光化合物及其制备方法和应用 |
-
2021
- 2021-05-05 AU AU2021268345A patent/AU2021268345A1/en active Pending
- 2021-05-05 KR KR1020227042343A patent/KR20230005987A/ko unknown
- 2021-05-05 WO PCT/US2021/030940 patent/WO2021226269A1/en unknown
- 2021-05-05 MX MX2022013051A patent/MX2022013051A/es unknown
- 2021-05-05 CA CA3179702A patent/CA3179702A1/en active Pending
- 2021-05-05 IL IL297898A patent/IL297898A/en unknown
- 2021-05-05 JP JP2022567515A patent/JP2023525040A/ja active Pending
- 2021-05-05 BR BR112022022530A patent/BR112022022530A2/pt unknown
- 2021-05-05 EP EP21800835.7A patent/EP4146205A1/en active Pending
- 2021-05-05 PE PE2022002553A patent/PE20230309A1/es unknown
- 2021-11-11 US US17/524,169 patent/US11667649B2/en active Active
-
2022
- 2022-06-07 US US17/834,127 patent/US20230076627A1/en active Pending
- 2022-11-03 CL CL2022003046A patent/CL2022003046A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230076627A1 (en) | 2023-03-09 |
US20220098212A1 (en) | 2022-03-31 |
CA3179702A1 (en) | 2021-11-11 |
CL2022003046A1 (es) | 2023-10-06 |
WO2021226269A1 (en) | 2021-11-11 |
US11667649B2 (en) | 2023-06-06 |
JP2023525040A (ja) | 2023-06-14 |
KR20230005987A (ko) | 2023-01-10 |
IL297898A (en) | 2023-01-01 |
AU2021268345A1 (en) | 2022-11-10 |
EP4146205A1 (en) | 2023-03-15 |
MX2022013051A (es) | 2023-01-24 |
US20220340586A9 (en) | 2022-10-27 |
PE20230309A1 (es) | 2023-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022022530A2 (pt) | Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk | |
BR112022022535A2 (pt) | Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk | |
BR112023021111A2 (pt) | Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2 | |
CY1123186T1 (el) | Μακροκυκλικοι mcl1 αναστολεις για τη θεραπευτικη αντιμετωπιση του καρκινου | |
BR112021008524A8 (pt) | 2-amino-n-heteroaril-nicotinamidas como inibidores de nav 1.8 | |
BR112018007526A2 (pt) | compostos de benzolactama como inibidores de proteína quinase | |
BR112022017393A2 (pt) | Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto | |
DE60309701D1 (de) | 2-ureido-6-heteroaryl-3h-benzoimidazol-4-carbonsäurederivate und verwandte verbindungen als gyrase und/oder topoisomerase iv inhibitoren zur behandlung von bakteriellen infektionen | |
BR112022024476A2 (pt) | 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8 | |
EA200801041A1 (ru) | Ингибиторы мек и способы их применения | |
BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
BR112022025805A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir um distúrbio, condição ou doença | |
BR112015006990A2 (pt) | composto, composição farmacêutica, e, uso de pelo menos um composto | |
BR112022024450A2 (pt) | 2-oxo-oxazolidina-5-carboxamidas como inibidores de nav1.8 | |
EA200971026A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
TN2010000204A1 (en) | Kinesin inhibitors as cancer therapeutics | |
BRPI0716069A2 (pt) | composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio | |
BR112022014480A2 (pt) | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit | |
EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
CL2023001461A1 (es) | Inhibidores de prmt5 novedosos | |
MX2022009059A (es) | Compuestos heterociclicos novedosos utiles como inhibidores selectivos de aurora a. | |
MX2022009197A (es) | Metodos de tratamiento para deficiencia de alfa-1 antitripsina. | |
BR112023023186A2 (pt) | 3-oxopiperazina carboxamidas de arila e 3-oxopiperazina carboxamidas de heteroarla como inibidores de nav1.8 | |
BR112021019817A2 (pt) | Compostos de pirrol | |
BR112012015129A2 (pt) | "composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio" |